Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives

Drug Design and Discovery

Volumn 14, Issue 4, 1997, Pages 305-332

  Font, Maria ^a   Monge, Antonio ^a   Alvarez, Elena ^a   Cuartero, Ana ^a   Losa, María José ^a   Fidalgo, María José ^a   Sanmartín, Carmen ^a   Nadal, Eva ^a   Ruiz, Inmaculada ^a   Merino, Isidro ^a   Martínez Irujo, Juan J ^a   Alberdi, Elena ^a   Santiago, Esteban ^a   Prieto, Isidro ^a   Lasarte, Juan J ^a   Sarobe, Pablo ^a   Borrás, Francisco ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

HIV 1 RT nonnucleoside inhibitors; HIV 1(IIIB) HLT41acZ 1 cells; Quinoline; Quinoxaline; Syncytia assay

Indexed keywords

ANTIINFECTIVE AGENT; BUTYL 2 CYANO 1 (2H) QUINOLINCARBOXYLIC ACID; ISOBUTYL 2 CYANO 1 (2H) QUINOLINCARBOXYLIC ACID; ISOPROPYL 2 CYANO 1 (2H) QUINOLINCARBOXYLIC ACID; PROPYL 2 CYANO 1 (2H) QUINOLINCARBOXYLIC ACID; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT;

ANTI-HIV AGENTS; CELL LINE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; QUINOLINES; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8244230512     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Coffin, J. M. (1995). HIV population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis and Therapy. Science, 267, 483-489.
2. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W , Leonard, J. M. and Markowitz, M. (1995). Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature, 373, 123-126.
3. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deustch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. and Shaw, G. M. (1995). Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection. Nature, 373, 117-122.
4. Ball, J. K., Holmes, E. C., Whitwell, H. and Desselber, U. (1994). Genomic Variation of Human Immunodeficiency Virus Type 1 (HIV-1): Molecular Analyses of HIV-1 in Sequential Blood Samples and Various Organs Obtained at Autopsy. J. Gen. Virol., 75, 867-869.
5. Goodenow, M., Huet, T., Saurin, W., Kwok, S., Sninsky, J. and Wain-Hobson, S. (1989). HIV-1 Isolates are Rapidly Evolving Quasispecies: Evidence for Viral Mixtures and Preferred Nucleotide Substitutions. J. Acquired. Immune Def. Syndr., 2, 344-352.
6. Groenink, M., Fouchier, R. A. M., de Goede, R. E. Y., de Wolf, F., Gruters, R. A., Cuypers, H. T. M., Huisman, H. G. and Tersmette, M. (1991). Phenotypic Heterogeneity in a Panel of Infectious Molecular Human Immunodeficiency Virus Type 1 Clones Derived from a Single Individual. J. Virol., 65, 1968-1975.
7. Delassus, S., Cheynier, R. and Wain-Hobson, S. (1992). Non-homogeneous Distribution of Human Immunodeficiency Virus Type 1 Proviruses in the Spleen. J. Virol., 66, 5642-5645.
8. Coffin, J. M. (1992). Genetic Diversity and Evolution of Retroviruses. Curr. Top. Microbiol. Immunol., 176, 143-64.
9. Nájera, I., Holguín, A., Quin̄ones-Mateu, M. E., Mun̄oz-Fernández, M. A., Nájera, R., López-Galíndez, C., Domingo, E. (1995). pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in Virus from Patients Undergoing No-Drug Therapy. J. Virol., 69, 23-31.
10. Buckheit, R. W. Jr, Fliakas-Boltz, V., Yeagy-Bargo, S., Weislow, O., Mayers, D. L., Boyer, P. L., Hughes, S. H., Pan, B., Chu, S. and Bader, J. P. (1995). Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine Derivatives is Generated by mutations at multiple sites in the HIV-1 Reverse Transcriptase. Virology, 210, 186-193.
11. Smerdon, S. J., Jager, J., Wang, J., Kohlstaedt, L. A., Chirino, A. J., Friedman, J. M., Rice, P. A. and Steitz, T. A (1994). Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA, 91, 391-395.
12. Nanni, R. G., Ding, J., Jacobo-Molina, A., Hughes, S. H. and Arnold, E. (1993). Review of HIV-1 reverse transcriptase Three Dimensional Structure: Implication for Drug Design, Perspectives in Drug Design and Discovery, 1, 129-150.
13. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer, P. and Arnold, E. (1994). Location of anti-AIDS drug binding sites and resistance mutations in the 3-D structure of HIV-1 RT. J. Mol. Biol., 243, 369-387.
14. Larder, B. A., Kemp, S. D. and Harrigan, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science, 269, 696-699.
15. Font, M., Monge, A., Cuartero, A., Elorriaga, A., Martínez-Irujo, J. J., Alberdi, E., Santiago, E., Prieto, I., Lasarte, J. J., Sarobe, P. and Borrás, F. (1995). Indoles and Pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 Reverse Transcriptase, Eur J. Med. Chem., 30, 963-971.
16. th International Symposium on Medicinal Chemistry, París, France.
17. Strekowski, L., Mokrosz, M. J., Honkan, V. A., Czarny, A., Cegla, M. T., Wydra, R. L., Patterson, S. E. and Schinazi, R. F. (1991). Synthesis and Quantitative - Structure Activity Relationships Analyses of 2-(Aryl or Heteroaryl)quinolin-4-amines, a New Class of Anti-HIV-1 Agents. J. Med. Chem., 34, 1739-1746.
18. Althaus, I. W., Gonzales, A. J., Chou, J. J., Romero, D. L., Deibel, M. R., Chou, K.-C., Kezdy, F. J., Resnick, L., Busso, M. E., So, A. G., Downey, K. M., Thomas, R. C., Aristoff, P. A., Tarpley, W. G. and Reusser, F. (1993). The Quinoline U-78036 is a Potent Inhibitor of HIV-1 Reverse Transcriptase. J. Biol. Chem., 268, 14875-14880.
19. Kleim, J.-P., Bender, R., Billhardt, U.-M., Meichsner, C., Riess, G., Rosner, M., Winkler, I. and Paessens, A. (1993). Activity of a Novel Quinoxaline Derivative against Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Viral Replication. Antimicrob. Agents Chemother., 37, 1659-1664.
20. Klein, J.-P., Bender, R., Kirsch, R., Meichsner, C., Paessens, A., Rösner, M., Rübsamen-Waigmann, H., Kaiser, R., Wichers, M., Schneweis, K. E., Winkler, I., Reiss, G. (1995) Antimicrob. Agents Chemother. 39, 2253-2257.
21. Balzarini, J., Karlsson, A., Meichsner. C., Paessens, A., Reiss, G., De Clercq, E. and Kleim, J. P. (1994). Resistance pattern of Human Immunodeficience virus type 1 reverse transcriptase to quinoxaline S-2720 J. Virol., 68, 7986-7992
22. Kleim, J.-P., Rösner, M., Winkler, I., Paessens, A., Kirsch, R., Hsiou, Y., Arnold, E. and Reiss, G. (1996). Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RTLeu74-Val or Ile and Va175-Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA, 93, 34-38.
23. Deibel, M. R., McQuade, T. J., Brunner, D. P. and Tarpley, W. G. (1990). Denaturation/Refolding of Purified Recombinant HIV Reverse Transcriptase Yields Monomeric Enzyme with High Enzymatic Activity. AIDS Res. Hum. Retroviruses, 6, 329-340.
24. Tan, C.-K., Zhang, J., Li, Z.-Y., Tarpley, W. G., Downey, K. M. and So, A. G. (1991). Functional Characterization of RNA-Dependent DNA Polymerase and RNaseH Activities of a Recombinant HIV Reverse Transcnptase. Biochemistry, 30, 2651-2655.
25. Sharma, S. K., Evans, D. B., Vorters, A. F., McQuade, T. J. and Tarpley, W. G. (1991). Metal Affinity Chromatography of Recombinant HTV-1 Reverse Transcriptase Containing a Human Renin Cleavable Metal Binding Domain. Biotechnol. Appl. Biochem., 14, 69-81.
26. Rocancourt, D., Bonnerot, C., Jouin, H., Emerman, M. and Nicolas, J. F. (1990). Activation of a Beta-galactosidase Recombinant Provirus: Application to Titration of Human Immunodeficiency Virus (HIV) and HIV-Infected Cells. J. Virol., 64, 2660-8.
27. Aggarwal, B. B., Kohr, W. J., Hass, P. E., Moffat, B., Spencer, S. A., Henzel, W. J., Bringman, T. S., Nedwin, G. E., Goeddel, D. V. and Harkins, R. N. (1985). Human Tumor Necrosis Factor. Production, Purification and Characterization. J. Biol. Chem., 260, 2345-54.
28. Dueweke, T. J., Pushkarskaya, T., Poppe, S. M., Swaney, S. M., Zhao, J. Q., Chen, I. S., Stevenson, M. and Tarpley, W. G. (1993). A mutation in reverse transcriptase of bis(heteroaryl)pyperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA, 90, 4713-4717.
29. Popp, F. D. (1968). Reissert Compounds. Adv. Heterocyclic Chem. 9, 1-25.
30. Popp, F. D. (1982). In The Chemistry of Heterocyclic Compounds: The Quinolines Ed. G. Jones, Part 2, Wiley Interscience. New York, 353.
31. Popp, F. D. (1979). Developments in the Chemistry of Reissert Compounds (1968-1978). Adv. Heterocyclic Chem. 28, 187-214.
32. Cooney, J. V. (1983). Reissert Compounds and their Open Chain Analogs in Organic Synthesis, J. Het. Chem, 20, 823-37.
33. Ruchirawat, S., Phadungkul, N., Chunankamnerdkan, M. and Thebtarononth, C. (1977). A Versatile Synthesis of Reissert Compounds. Heterocycles, 246, 43-6.
34. Popp, F. D. (1980). Reissert Compounds Derived from Diazaromatic Systems. Heterocycles, 14, 1033-43.
35. Blatchly, R. A., Greeley, M. A. and Markgraft, J. H. (1989). The Skraup Reaction of 3,4-Dihaloanilines. Heterocycles, 29, 2345-2351.
36. Cobb, L. and Mc Ewen, W. E. (1955). Mechanism of the Acid Catalyzed Hydrolisis of Reissert Compounds. J. Am. Chem. Soc., 77, 5042-5048.
37. Veeraragharan, S. and Popp, F. D. (1982). Reissert Compounds Studies. XLIII. The Pyrido[2,3-b]pyrazine Reissert Compounds. J. Het. Chem., 19, 425-426.
38. Popp, F. D., Katz, L. E., Klinowski, C. W. and Wefer, J. M. (1968). Reissert Compounds Studies. XVIII. Analogs Derived from Chloroformates, J. Org. Chem. 33, 4447-4450.
39. Snoke, E. O. and Popp, F. D. (1973). Synthesis of Potential Antineoplastic Agents. XXIII. Compounds Related to Methyl 2-Cyano-1(2H)quinolinecarboxylate (1). J. Het. Chem., 10, 99-101.